A Phase 2 Double-Blind, Repeat-Dose, Placebo-Controlled Crossover Study To Evaluate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia
Clinical Trial Grant
Awarded By
Cardurion Pharmaceuticals, Inc.
Start Date
October 23, 2025
End Date
September 30, 2027
Awarded By
Cardurion Pharmaceuticals, Inc.
Start Date
October 23, 2025
End Date
September 30, 2027